1. Scrip
  2. >>Business
  3. >>Strategy

Biotech Models: Bypassing VCs to Deal Direct with Pharma

 
• By Melanie Senior

There has to be a better way to do biotech than lurching from one hard-fought VC round to the next, losing sight of product development for the sake of providing an exit for investors. That's the view of HS LifeSciences, which aims to create a more direct route from promising academic research to market, avoiding the management time, heartache and dilution associated with serial VC rounds. Put simply, the idea is to match innovative technologies or research projects with potential pharma partners very early on, bypassing VC funding and allowing maximum resource and attention to be focused on the product.

There has to be a better way to do biotech than lurching from one hard-fought VC round to the next, losing sight of product development for the sake of providing an exit for investors. That’s the view of (among others) biotech entrepreneurs Karsten Henco, PhD, and Edward Stuart, PhD, founders and Chairman and CEO respectively of Zurich-based consultancy HS LifeSciences. They’ve set up HS LifeSciences to help create a more direct route from promising academic research to market, avoiding the management time, heartache and dilution associated with serial VC rounds.

Put simply, the idea is to match innovative technologies or research projects with potential pharma partners very early on, bypassing...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

In Brief: BioVersys And Shionogi Align In Non-Tuberculous Mycobacteria R&D

 
• By Joseph Haas

Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By Kevin Grogan

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.

Protagonist Hopes To Come From Behind In Obesity With Oral Triple Agonist

 
• By Jessica Merrill

The company announced plans to move an oral GLP-1/GIP/GCG receptor agonist peptide into clinical development for obesity in 2026.

In Brief: Sanofi Cements Support For Adagene

 
• By Kevin Grogan

Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.

More from Business

In Brief: Sanofi Cements Support For Adagene

 
• By Kevin Grogan

Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.

In Vivo CAR-T Interest Grows With AbbVie Acquisition

 
• By Andrew McConaghie

Acquiring Capstan gives AbbVie a stake in two competing in vivo CAR-T delivery platforms, with the field's first readouts expected in 2026.

Stock Watch: Syncona’s Wild Ride Exposes Suspect Strategies

 
• By Andy Smith

A track record of positive portfolio performance is described as an investment management skill. Taking difficult divestment decisions early, in challenging markets and outperforming benchmarks, are hallmarks of this skill. Syncona and Woodford Patient Capital offer useful case studies.